Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
LENSAR, Inc. is a medical device company focused on the development and commercialization of advanced laser systems for use in ophthalmic surgery, specifically cataract surgery. The company’s core offering is a femtosecond laser platform designed to improve precision and reproducibility in cataract procedures, supporting surgeons with image-guided treatment planning and automated surgical steps. LENSAR historically generated revenue through the sale of laser systems, related consumables, software upgrades, and service contracts to hospitals, ambulatory surgery centers, and ophthalmology practices.
Founded in 2004, LENSAR positioned itself as a technology-driven innovator in the cataract surgery market, differentiating its platform through proprietary imaging, treatment planning software, and adaptive laser delivery. The company operated in a highly regulated segment of the medical technology industry, competing with larger diversified ophthalmic companies. In 2024, LENSAR, Inc. entered into a definitive acquisition agreement with Alcon Inc., and based on publicly available filings and transaction disclosures, LENSAR became a wholly owned subsidiary of Alcon following completion of the transaction. As a result, LENSAR no longer operates as an independent publicly traded company.
Business Operations
Prior to its acquisition, LENSAR operated primarily through a single reportable business segment focused on ophthalmic laser systems for cataract surgery. Revenue was derived from capital equipment sales of its femtosecond laser platform, recurring revenue from procedure-based disposables, and ongoing service and maintenance agreements. The company also generated limited revenue from software-related enhancements tied to its laser systems.
Operationally, LENSAR maintained research and development capabilities centered on imaging, laser physics, and surgical workflow optimization, while manufacturing and certain components were outsourced to specialized suppliers. Commercial activities were conducted through a direct sales force in key markets and through distributor relationships internationally. Following the acquisition, LENSAR’s technology, intellectual property, and product portfolio were integrated into Alcon’s global surgical franchise, and LENSAR now operates as a subsidiary rather than a standalone operating entity.
Strategic Position & Investments
LENSAR’s strategic focus prior to acquisition was centered on expanding adoption of laser-assisted cataract surgery by emphasizing clinical precision, workflow efficiency, and surgeon control. Growth initiatives included enhancements to its proprietary imaging and planning software, increased penetration in outpatient surgical centers, and selective international expansion through distribution partners.
The most significant strategic transaction in the company’s history was its acquisition by Alcon Inc., a global leader in eye care. This transaction represented a strategic exit for LENSAR and positioned its femtosecond laser technology within Alcon’s broader cataract and refractive surgery ecosystem. LENSAR did not maintain a diversified investment portfolio or multiple operating subsidiaries prior to the acquisition; its primary strategic asset was its proprietary laser technology platform and related intellectual property.
Geographic Footprint
Historically, LENSAR’s headquarters were located in the United States, with primary operations, research activities, and corporate functions based domestically. The company generated the majority of its revenue from North America, where laser-assisted cataract surgery adoption was most established.
Internationally, LENSAR maintained a presence across parts of Europe, Asia-Pacific, and Latin America through distributor and reseller arrangements rather than direct subsidiaries. Following the acquisition, LENSAR’s technology and products became part of Alcon’s global footprint, significantly expanding its reach through Alcon’s established commercial infrastructure across the Americas, Europe, Asia, and emerging markets.
Leadership & Governance
Before becoming a wholly owned subsidiary, LENSAR was governed by a board of directors and led by an executive management team with experience in medical devices and ophthalmology. Strategic leadership emphasized technological differentiation, regulatory compliance, and preparation for scale within a competitive market dominated by larger players.
Key executives prior to the acquisition included:
- Nicholas Curtis – President and Chief Executive Officer
- Rich Erdmann – Chief Financial Officer
- Sean McCafferty – Chief Commercial Officer
- Randy Frey – Chief Technology Officer
Following the acquisition by Alcon Inc., governance and executive oversight transitioned to Alcon’s leadership structure. Public disclosures indicate that detailed post-acquisition leadership assignments specific to the LENSAR business are not fully delineated in standalone form; data inconclusive based on available public sources.